Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue , 2015, Pages

  Powderly, John ^a   Cote, Gregory ^b   Flaherty, Keith ^b   Szmulewitz, Russell Z ^c   Ribas, Antoni ^d   Weber, Jeffrey ^e   Loo, Deryk ^f   Baughman, Jan ^f   Chen, Francine ^f   Moore, Paul ^f   Bonvini, Ezio ^f   Vasselli, James ^f   Wigginton, Jon ^f   Cohen, Roger ^g   Burris, Howard ^h   Chmielowski, Bartosz ⁱ  

^a Carolina BioOncology Institute   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f Analytical Sciences   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h SARAH CANNON RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD276 ANTIGEN; CORTICOSTEROID; ENOBLITUZUMAB; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; INFUSION RELATED REACTION; MELANOMA; NAUSEA; NEOPLASM; PHARMACODYNAMICS; PHARMACOKINETIC ASSAY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR VASCULARIZATION; VOMITING;

EID: 85041595792     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/2051-1426-3-S2-O8     Document Type: Article

References (0)